XT
IBRX icon

XTX Topco’s ImmunityBio IBRX Stock Holding History

XTX Topco’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Sell
131,918
-257,184
-66% -$1.95M 0.02% 1665
2026
Q1 		$2.98M Buy
+389,102
New +$2.66M 0.05% 567
2025
Q3 		– Sell
-28,719
Closed -$75.8K – 2865
2025
Q2 		$75.8K Sell
28,719
-82,928
-74% -$223K ﹤0.01% 1932
2025
Q1 		$336K Buy
111,647
+5,764
+5% +$17.5K 0.02% 1316
2024
Q4 		$271K Buy
105,883
+12,973
+14% +$54K 0.02% 1301
2024
Q3 		$346K Buy
92,910
+70,215
+309% +$325K 0.03% 1097
2024
Q2 		$143K Sell
22,695
-13,732
-38% -$90.5K 0.01% 1337
2024
Q1 		$196K Buy
+36,427
New +$165K 0.03% 1186
2023
Q1 		– Sell
-38,589
Closed -$196K – 1456
2022
Q4 		$196K Buy
38,589
+25,952
+205% +$143K 0.04% 852
2022
Q3 		$63K Buy
+12,637
New +$57.6K 0.02% 1004
2022
Q1 		– Sell
-19,159
Closed -$116K – 797
2021
Q4 		$116K Buy
+19,159
New +$144K 0.07% 443

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

XTX Topco's IBRX Position: Q2 2026 in Review

XTX Topco reduced its ImmunityBio (IBRX) stake by 66% in Q2 2026, selling an estimated $1.95M and leaving 131,918 shares worth $1.15M. The position accounts for 0.02% of the portfolio, ranked #1665.

XTX Topco first reported a position in IBRX in Q4 2021 and has held it in 11 quarters since. The position peaked at $2.98M in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • XTX Topco held 131,918 shares of ImmunityBio worth $1.15M as of Q2 2026.
  • XTX Topco sold 257,184 ImmunityBio shares in Q2 2026, an estimated $1.95M.
  • ImmunityBio made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1665 holding.
  • XTX Topco first reported a position in ImmunityBio in Q4 2021 and has held it in 11 quarters since.
  • XTX Topco's ImmunityBio position peaked at $2.98M in Q1 2026.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.